Literature DB >> 3714348

Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters.

M L Disis, T L McDonald, J L Colombo, R H Kobayashi, C R Angle, S Murray.   

Abstract

Circulating immune complexes (CIC) have been found to be elevated in individuals with cystic fibrosis (CF). Previous investigators, using a variety of assays, have reported high levels of CIC in as many as 86% of these patients. Our study followed the progress of 25 patients with CF over a period of 10 months to determine which, if any, clinical parameters correlated with the occurrence and/or concentration of CIC. Immune complex determinations were performed using a coprecipitation method with equine rheumatoid-complement complex. One hundred percent of the CF patients had CIC elevated above normal levels, however, levels of CIC did not correlate with the severity of an individual's acute exacerbation. Clinical parameters including pulmonary function tests, vital signs, total serum IgG levels, and other laboratory studies, were obtained on each individual and analyzed with respect to their relationship to CIC. Only four of 38 parameters examined had p less than 0.05. Factors that showed significant correlation to elevated CIC's in the highly elevated portion of our CIC population were poor NIH score, increased patient age, low peak expiratory flow rate, and elevated total serum IgG. These clinical values are associated more with the measurement of chronic disease. These data suggest that CICs cannot be used as an indication of short-term prognosis or as a monitor to follow the course of acute severe lung infections in the CF patient. Of interest was the observation that all patients who died during the course of the investigation had CIC levels greater than 80 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3714348     DOI: 10.1203/00006450-198605000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results.

Authors:  M Mirić; J Vasiljević; M Bojić; Z Popović; N Keserović; M Pesić
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 2.  Joint disorders in cystic fibrosis.

Authors:  M A Turner; E Baildam; L Patel; T J David
Journal:  J R Soc Med       Date:  1997       Impact factor: 5.344

3.  Effect of prenatal lignocaine on auditory brain stem evoked response.

Authors:  M E Bozynski; R E Schumacher; L S Deschner; P Kileny
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

Review 4.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

5.  Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia.

Authors:  M A Mellencamp; L C Preheim; T L McDonald
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Prothrombotic abnormalities in inflammatory bowel disease.

Authors:  M G Conlan; W D Haire; D A Burnett
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.